Dataset Information

Proteomic signatures of the serological response to flu vaccination in a large human cohort study

ABSTRACT: This project investigates the serum proteomic signatures of the serological response to flu vaccination. We profiled the serum proteome of 160 flu vaccine recipients from a cohort study conducted in 2019-2020 season, with DIA-MS based proteomics. We compared the protein level between low and high responders based on the response measure seroconversion, as well as the adjusted seroconversion which excludes the confoudning effects of all the semographic factors recorded for these participants. We did the analysis for the composite seroconversion as well as for the individual strains. We also investigated the complex impact of age.

INSTRUMENT(S): Q Exactive HF

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Blood Serum

SUBMITTER: Shaohuan Wu

LAB HEAD: Christine Vogel

PROVIDER: PXD036718 | Pride | 2022-11-17

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	225_flu_vaccine_serum_samples_-_BGS_Factory_Report.xls	Xls
	U100_200805_04.raw	Raw
	U108_set8_201216.raw	Raw
	U118_set8_201216.raw	Raw
	U11_200805_02.raw	Raw

Items per page:

1 - 5 of 226

Publications

Proteomic Signatures of the Serological Response to Influenza Vaccination in a Large Human Cohort Study.

Wu Shaohuan S Pushalkar Smruti S Maity Shuvadeep S Pressler Matthew M Rendleman Justin J Vitrinel Burcu B Carlock Michael M Ross Ted T Choi Hyungwon H Vogel Christine C

Viruses 20221109 11

The serological response to the influenza virus vaccine is highly heterogeneous for reasons that are not entirely clear. While the impact of demographic factors such as age, body mass index (BMI), sex, prior vaccination and titer levels are known to impact seroconversion, they only explain a fraction of the response. To identify signatures of the vaccine response, we analyzed 273 protein levels from 138 serum samples of influenza vaccine recipients (2019-2020 season). We found that levels of pro ...[more]

PMID: 36366577

Similar Datasets

Project description:During pregnancy, the Zika virus (ZIKV) can be vertically transmitted, causing Congenital Zika Syndrome (CZS) in fetuses. ZIKV infection in early gestational trimesters increases the chances to develop CZS. This syndrome involves several pathologies with a difficult diagnosis, which usually occurs in the postnatal stage. In this work, we aim to identify biological processes and molecular pathways related to CZS development and propose a series of putative protein and metabolite biomarkers for CZS prognosis in early pregnancy trimesters. Twenty-five serum samples of pregnant women were analyzed. For biological analysis, samples were separated into 3 biological groups composed of a control group of healthy pregnant women and two groups of ZIKV-infected pregnant women bearing non- microcephalic and microcephalic fetuses. Control and ZIKV-infected groups - without microcephalic fetuses - were subdivided into healthy and Cognitive Developmental Delay (CDD) newborns for biomarker analysis. We detected over 1,000 proteins and 500 metabolites by bottom-up proteomics and untargeted metabolomics, respectively. Statistical approaches - (t-Student, Limma, ANOVA, and DIABLO) - were applied to find CZS differentially abundant proteins (DAP) and metabolites (DAM). Enrichment analysis (i.e., biological processes and molecular pathways) of the DAP and the DAM allowed us to identify the ECM organization and proteoglycans, amino acid metabolism, and arachidonic acid metabolism as signatures in the CZS development. Five proteins and four metabolites were selected as CZS biomarkers candidates. The protein-based model indicated superior performance values for the Vitamin K-dependent protein S, Selenoprotein P, Inter-alpha- trypsin inhibitor heavy chain H2, Kallistatin, and Protein Z-dependent protease inhibitor proteins. Furthermore, the metabolite-based model was able to predict CZS with a probability of 90%. Serum multi-omics analysis led us to propose for further studies nine potential biomarkers for CZS early prognosis with high sensitivity and specificity.